Zanubrutinib

ApprovedRecruiting

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Waldenström's Macroglobulinemia

Conditions

Waldenström's Macroglobulinemia

Trial Timeline

Oct 17, 2025 → Oct 31, 2028

NCT ID

NCT07169331

About Zanubrutinib

Zanubrutinib is a approved stage product being developed by BeOne Medicines for Waldenström's Macroglobulinemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07169331. Target conditions include Waldenström's Macroglobulinemia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07169331	Approved	Recruiting	Oct 17, 2025	Oct 31, 2028	Waldenström's Macroglobulinemia
NCT05640102	Pre-clinical	Recruiting	Mar 3, 2023	Dec 1, 2027	Waldenstrom Macroglobulinemia
NCT05596097	Phase 2	Recruiting	Oct 30, 2022	Jul 30, 2026	Diffuse Large B-cell Lymphoma (DLBCL)
NCT04172246	Phase 1/2	Completed	Jan 29, 2020	Jun 30, 2025	Mature B-cell Malignancies
NCT04116437	Phase 2	Completed	Oct 15, 2019	Jan 9, 2026	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Competing Products

1 competing product in Waldenström's Macroglobulinemia

See all competitors

Product	Company	Stage	Hype Score
Zanubrutinib + Obinutuzumab	BeOne Medicines	Pre-clinical	20

Other Products from BeOne Medicines

Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007Phase 3

Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-FluorouracilPhase 3

Zanubrutinib + Bendamustine + Rituximab + VenetoclaxPhase 3

Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + CarboplatinPhase 3

Sonrotoclax + Zanubrutinib + PlaceboPhase 3